Commentary: A case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability

Oncologist

Volumn 12, Issue 7, 2007, Pages 808-815

  Chattopadhyay, Shrikanta ^a   Tamari, Roni ^a   Min, Sang H ^a   Zhao, Rongbao ^a   Tsai, Eugenia ^a   Goldman, I David ^a,b  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antifolates; Folate pools; Folic acid; Pemetrexed

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; HOMOCYSTEINE; PEMETREXED; TRIMETREXATE;

CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR CELL LINE; VITAMIN SUPPLEMENTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; TETRAHYDROFOLATES;

EID: 34548207202     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-7-808     Document Type: Review

References (34)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
2. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
3. Habeck LL, Mendelsohn LG, Shih C et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995;48:326-333.
4. Zhao R, Babani S, Gao F et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-3695.
5. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
6. Taylor EC, Kuhnt D, Shih C et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[ 2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4454.
7. Galivan J, Nimec Z, Balinska M. Regulation of methotrexate polyglutamate accumulation in vitro: Effects of cellular folate content. Biochem Pharmacol 1983;32:3244-3247.
8. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-865.
9. Zhao R, Zhang S, Hanscom M et al. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11:1294-1301.
10. van der Wilt CL, Backus HH, Smid K et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 2001;61:3675-3681.
11. Backus HH, Pinedo HM, Wouters D et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000;87:771-778.
12. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
13. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/ antimetabolite. Proc Am Soc Clin Oncol 2001;20:76a.
14. Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
15. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 1998;18:3235-3239.
16. Alati T, Worzalla JF, Shih C et al. Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetrahydrofolate-by oral folic acid. Cancer Res 1996;56:2331-2335.
17. Roberts JD, Poplin EA, Tombes MB et al. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 2000;45:103-110.
18. Jacques PF, Selhub J, Bostom AG et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-1454.
19. Quinlivan EP, Gregory JF 3rd, Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 2003;77:221-225.
20. Wald NJ, Law MR, Morris JK et al. Quantifying the effect of folic acid. Lancet 2001;358:2069-2073.
21. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-812.
22. van Oort FV, Melse-Boonstra A, Brouwer IA et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: A dose-response study. Am J Clin Nutr 2003;77:1318-1323.
23. Pfeiffer CM, Caudill SP, Gunter EW et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: Results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 2005;82:442-450.
24. Voeller DM, Allegra CJ. Intracellular metabolism of 5- methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line. Cancer Chemother Pharmacol 1994;34:491-496.
25. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
26. Zhao R, Gao F, Hanscom M et al. A prominent low-pH methotrexate transport activity in human solid tumor cells: Contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-727.
27. Zhao R, Chattopadhyay S, Hanscom M et al. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 2004;10:8735-8742.
28. Chattopadhyay S, Zhao R, Krupenko SA et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006;5:438-449.
29. Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-3016.
30. Melse-Boonstra A, de Bree A, Verhoef P et al. Dietary monoglutamate and polyglutamate folate are associated with plasma folate concentrations in Dutch men and women aged 20-65 years. J Nutr 2002;132:1307-1312.
31. Hazarika M, White RM, Johnson JR et al. FDA drug approval summaries: Pemetrexed (Alimta). The Oncologist 2004;9:482-488.
32. Eli Lilly and Company. Alimta® product information. In: Physicians' Desk Reference. Montvale, NJ: Thomson PDR, 2005:1824-1828.
33. Dietrich M, Brown CJ, Block G. The effect of folate fortification of cerealgrain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr 2005;24:266-274.
34. Niyikiza C, Hanauske AR, Rusthoven JJ et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002;29(suppl 18):24-29.